Biography
Dr Aaron Kent is a compassionate oncologist dedicated to patient-centred care. With a strong focus on clear communication, Dr Kent ensures patients and their families are fully informed and supported at each stage of what can be a complex and challenging time. Driven by a commitment to achieve the best possible outcome, Dr Kent combines clinical expertise with empathy to ensure every patient feels valued and respected.
Dr Kent is a highly experienced radiation oncologist with subspecialty expertise in genitourinary cancer, prostate brachytherapy, stereotactic body radiotherapy (SABR) and stereotactic radiosurgery (SRS). He was awarded a Bachelor of Medicine and Bachelor of Surgery with Honours and completed specialist training at The Alfred and Peter MacCallum Cancer Centre. Dr Kent was awarded Fellowship of the Royal Australian and New Zealand College of Radiologists in Radiation Oncology in 2021.
Dr Kent has worked across several major Australian cancer centres and has extensive experience treating a broad range of cancers, including genitourinary, neuro-oncology, gastrointestinal and lung cancers. In 2024, he was awarded the Thomas Baker Fellowship, undertaking advanced training in prostate brachytherapy and stereotactic radiotherapy at The Christie Hospital, Manchester and The Royal Marsden in London, United Kingdom.
Alongside his clinical practice, Dr Kent is actively involved in research, teaching and professional leadership. He contributes to genitourinary cancer guideline development, clinical trials and Radiation Oncology Registrar education, with a strong commitment to evidence-based care and improving access to advanced radiation oncology treatments.
Publications
Kent AR, Forster R, Millar J, Martin J, Wegener E, Dickson S, Zwahlen D, Windisch P and Schroder C. A comprehensive systematic review and meta-analysis of postoperative hypofractionation for prostate cancer patients. Submitted July 2026 International Journal of Radiation Oncology, Biology, Physics.
Kent AR, Matheson B, Millar JL. Improved survival for patients with prostate cancer receiving high-dose-rate brachytherapy boost to EBRT compared with EBRT alone. Brachytherapy. 2019 May 1;18(3):313-21.
Zaman FY, Orchard SG, Polekhina G, Gibbs P, Bernstein WB, Macrae F, Tie J, Millar J, Gately L, Rodríguez LM, van Londen GJ, Mar V, Hiscutt E, Adler N, Kent AR, Ong WL, Haydon A, Warner E, Chan AT, Zalcberg J. Association of non-steroidal anti-inflammatory medications and aspirin with colorectal cancer incidence in older adults, JNCI: Journal of the National Cancer Institute, Volume 117, Issue 9, September 2025, Pages 1875–1882
Orchard SG, Polekhina G, Zalcberg J, Bernstein W, Macrae F, Tie J, Gately L, Mar V, Millar J, Rodriguez LM, Van Londen GJ, Kent AR, Hiscutt E, Ong WL, Warner ET, Ford L, Umar A, McNeil JJ, Nelson M, Stocks N, Shah RC, Kirsch B, Murray A, Woods RL, Ryan J, Wolfe R, Gibbs P and Chan AT. Cancer incidence and mortality with aspirin in older adults: follow-up of the ASPREE trial. JAMA oncology. 2026 Mar;12(3):285-94.